食欲调节激素——瘦素、脂联素和胃饥饿素——与前列腺癌发生:系统综述与探索性Meta分析
该系统综述与探索性Meta分析遵循PRISMA指南,检索截至2019年3月的PubMed、EMBASE和Web of Science数据库,纳入35项观察性研究,评估血清瘦素、脂联素或胃饥饿素水平与前列腺癌发生、晚期疾病发生或前列腺癌特异性死亡的关系。Meta分析采用随机效应模型计算meta相对危险度(mRR),结果显示瘦素与前列腺癌发生或晚期前列腺癌无显著关联,脂联素最高水平男性晚期前列腺癌合并风险降低但未达统计学显著,胃饥饿素研究尚不充分。
要点
- 瘦素与前列腺癌发生(mRR=0.93,95%CI 0.75-1.16,p=0.52)或晚期前列腺癌(mRR=0.90,95%CI 0.74-1.10,p=0.30)均无显著关联。
- 脂联素最高水平男性晚期前列腺癌合并风险降低但未达统计学显著(mRR=0.81,95%CI 0.61-1.08,p=0.15)。
- 胃饥饿素与前列腺癌结局的研究尚不充分,原文未报告相关合并风险估计。
核心结论
- 当前证据不提示瘦素与前列腺癌结局存在关联。
- 脂联素与晚期前列腺癌发生之间可能存在反向关联,作者认为需进一步研究。
- 血清胃饥饿素尚未得到充分研究。
研究设计与样本
- 遵循PRISMA指南的系统综述与探索性Meta分析。
- 系统检索PubMed、EMBASE和Web of Science数据库截至2019年3月发表的相关文章。
- 纳入报告血清瘦素、脂联素或胃饥饿素水平与前列腺癌结局数据的观察性研究。
- 共35项研究符合纳入标准。
- 采用随机效应模型计算meta相对危险度(mRR),有原始数据时进行合并,通过漏斗图和Begg检验评估发表偏倚。
主要发现
- 定性分析提示瘦素与任何前列腺癌结局均无一致性关联,但若干队列报告后来发生晚期前列腺癌的男性脂联素水平降低。
- 瘦素对前列腺癌发生无显著影响(mRR=0.93,95%CI 0.75-1.16,p=0.52)。
- 瘦素对晚期前列腺癌无显著影响(mRR=0.90,95%CI 0.74-1.10,p=0.30)。
- 脂联素最高水平男性晚期前列腺癌合并风险降低但未达统计学显著(mRR=0.81,95%CI 0.61-1.08,p=0.15)。
- 脂联素最高水平男性前列腺癌发生的mRR因研究不足无法估计。
关键数值与推荐
- 瘦素与前列腺癌发生:mRR=0.93(95%CI 0.75-1.16),p=0.52。
- 瘦素与晚期前列腺癌:mRR=0.90(95%CI 0.74-1.10),p=0.30。
- 脂联素最高水平与晚期前列腺癌:mRR=0.81(95%CI 0.61-1.08),p=0.15。
临床怎么用
- 原文未据此给出推荐。
局限性
- 脂联素最高水平男性前列腺癌发生的mRR因研究不足无法估计。
- 血清胃饥饿素尚未得到充分研究。
- 脂联素与晚期前列腺癌发生的可能反向关联需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity has been proposed as a risk factor for prostate cancer (PCa). In obesity, serum levels of the appetite-regulating hormones-leptin, adiponectin, and ghrelin-become deregulated. OBJECTIVE: To explore whether serum levels of appetite-regulating hormones associate with the incidence of PCa, the incidence of advanced disease, or PCa-specific mortality. METHODS: PRISMA guidelines were followed. A systematic search for relevant articles published until March 2019 was performed using the databases PubMed, EMBASE, and Web of Science. Observational studies with data on serum levels of leptin, adiponectin, or ghrelin and PCa outcome were included. Meta-analysis was used to combine risk estimates. Meta-relative risks (mRRs) were calculated using random effects models. When available, raw data was pooled. Publication bias was assessed by funnel plot and Begg's test. RESULTS: Thirty-five studies were eligible for inclusion. The qualitative analysis indicated that leptin was not consistently associated with any PCa outcome, although several cohorts reported decreased adiponectin levels in men who later developed advanced PCa. Based on the meta-analysis, there was no significant effect of leptin on PCa incidence (mRR = 0.93 (95% CI 0.75-1.16), p = 0.52) or advanced PCa (mRR = 0.90 (95% CI 0.74-1.10), p = 0.30). There were insufficient studies to estimate the mRR of PCa incidence for men with the highest levels of adiponectin. The combined risk of advanced PCa for men with the highest levels of adiponectin was reduced but did not reach significance (mRR = 0.81 (95% CI 0.61-1.08), p = 0.15). CONCLUSIONS: The current evidence does not suggest an association between leptin and PCa outcome. However, there may be an inverse association between adiponectin and the incidence of advanced PCa that should be investigated by further studies. Serum ghrelin has not been largely investigated.
引用
- Angel CZ, Iguacel I, Mullee A, et al. Appetite-regulating hormones-leptin, adiponectin and ghrelin-and the development of prostate cancer: a systematic review and exploratory meta-analysis. Prostate Cancer Prostatic Dis. 2019. PMID: 31147627. doi:10.1038/s41391-019-0154-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。